Viromed Medical AG reports promising study results for PulmoPlas in intensive care unit ventilator-associated pneumonia patients - Seite 2

As part of the extensive review of the procedure, the positive safety results announced today regarding the use of PulmoPlas will be validated via a second procedure.

The detailed results of the clinical study are expected to be published in early summer 2025. Based on the study results, Viromed plans to submit an application to the Federal Institute for Drugs and Medical Devices (BfArM) for marketing authorization of PulmoPlas as a medical device for the treatment of VAP.

Since 2022, the Hannover Medical School, in cooperation with Viromed Medical AG, has been investigating the safety of cold plasma in bacterial infections of the respiratory tract using respiratory mucosa models. The work has been on the potential of cold plasma to kill bacteria that cause VAP.

A second part of the clinical study (Project 2) with PulmoPlas for the prevention of VAP is ongoing, with results expected in 2026.

 

About Ventilator Associated Pneumonia and the use of cold plasma

Ventilator Associated Pneumonia (VAP) is a frequent, avoidable and serious complication in mechanically ventilated patients. It occurs in patients who are invasively mechanically ventilated for at least 48 hours. Study results show that VAP occurs in 23-36% of mechanically ventilated patients, and is associated with prolonged ventilation time, longer stays in the intensive care unit and hospital, as well as increased cost. The estimated mortality rate is 10-13%. In Germany alone, there were around 486,000 mechanically ventilated intensive care patients in 2023 and many thousands of deaths, with a strong upward trend. Worldwide, many millions of patients are mechanically ventilated every year.

Cold atmospheric plasma is an innovative physical, completely painless treatment method, that destroys viruses and bacteria in the respiratory tract in 30-90 seconds. Cold plasma is a groundbreaking innovation, particularly effective against antibiotic-resistant MRSA bacteria, as it destroys them. Antibiotics can take several hours or even days to reach the source of an infection, and are becoming increasingly ineffective due to the growing problem of multi-resistant germs. The use of cold plasma against VAP has the potential to reduce infections, accelerate healing, decrease antibiotic usage and, above all, save hundreds of thousands of lives every year.